Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-03-14, 10:25:37 | version 1.49.03
Drug development Using DNA-based technologies and human tissue models, we are elucidating host-pathogen interactions to identify new target structures for antibiotics and for boosting human immune defense. We are investigating potential active compounds using cell-based assays – e.g. for immunomodulatory substances – based structure-effect relationships. To analyze the effects and side effects of potential active compounds, we are developing three-dimensional in vitro tissue models and organ-on-a-chip systems based on human primary or iPS cells to replace animal tests. In addition, we are developing processes to produce pharmaceutical proteins: from the establishment of new expression vectors to strain development and puriication of the pharmaceuticals. Formulations and release systems Transport of a substance to their destination – e.g. a tissue or cell – is a key factor in the devel- opment of functional ingredients or active compounds. At Fraunhofer IGB, we are developing structures that transport substances to their site of action in a targeted manner (drug delivery) and release them there in a controlled manner (drug release). For example, we are formulating active compounds in a matrix consisting of biobased, polymer or siliceous material in the form of (nano)particles or layers. To achieve this, we are using various techniques such as spray tech- nologies, solvent evaporation, emulsions or dispersions. Using virus-like particles as vehicles, we are persuing a new approach to packaging and targeted transport of active compounds. Food and cosmetics Our aim in this topic area is the extraction of functional ingredients from biogenic raw or residual materials, from intermediate products in agricultural and food production and from microalgae. For this purpose, we are developing gentle-to-product and eficient procedures to extract (supercritical luids, high-pressure in combination with pressure change technology) and purify the products using electrophoretic and mechanic separation processes. In addition, we are developing new physical processes to stabilize and conserve food, cosmetics, drug substances and plant extracts. Since this procedure is carried out at low temperatures below 50°C, the biological function of valuable ingredients, such as vitamins is not affected during the treatment. 4 8